S. Tam

Multivariate analysis of expression of the microtubule-associated protein, tau, predicts improved progression free and overall survival in patients with metastatic HER-2-negative breast cancers treated with docetaxel and vinorelbine plus filgrastim.

L. Goldstein, A. Gown, P. Porter, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.

Donatello Telesca, Roman Gulati, P. Nelson, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)

D. Mankoff, H. Linden, R. Livingston, 2007, Breast Cancer Research and Treatment.